Metastatic Hepatocellular Carcinoma Hcc clinical trials

Explore recruiting metastatic hepatocellular carcinoma hcc clinical trials.

Recruiting metastatic hepatocellular carcinoma hcc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Hepatocellular Carcinoma Hcc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3, Randomized Study to Evaluate the Optimized dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab in Subjects with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) who have not previously received systemic treatment

Italy, France, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination with Budigalimab for locally advanced or Metastatic Hepatocellular Carcinoma patients who have progressed after an approved immune checkpoint inhibitor containing regimen in First-Line HCC

France, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma (RELATIVITY-106)

Germany, Spain, France, Italy, Poland

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Metastatic Hepatocellular Carcinoma Hcc trials by city

Metastatic Hepatocellular Carcinoma Hcc in Toronto Metastatic Hepatocellular Carcinoma Hcc in Vancouver Metastatic Hepatocellular Carcinoma Hcc in Montreal Metastatic Hepatocellular Carcinoma Hcc in Calgary Metastatic Hepatocellular Carcinoma Hcc in Edmonton Metastatic Hepatocellular Carcinoma Hcc in Ottawa Metastatic Hepatocellular Carcinoma Hcc in Winnipeg Metastatic Hepatocellular Carcinoma Hcc in Quebec City Metastatic Hepatocellular Carcinoma Hcc in Hamilton Metastatic Hepatocellular Carcinoma Hcc in Kitchener Metastatic Hepatocellular Carcinoma Hcc in London Metastatic Hepatocellular Carcinoma Hcc in Halifax Metastatic Hepatocellular Carcinoma Hcc in New York Metastatic Hepatocellular Carcinoma Hcc in Los Angeles Metastatic Hepatocellular Carcinoma Hcc in Chicago Metastatic Hepatocellular Carcinoma Hcc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease